Characteristics of patients identified by mHOMR
| Site 1 | Site 2 | |||||||
| Phase 1 | Phase 2 | P value* | Effect size† | Phase 1 | Phase 2 | P value* | Effect size† | |
| N | 100 | 100 | 100 | 100 | ||||
| Age (months) (SD) | 83 (7.7) | 82 (7.7) | 0.292 | – | 84 (8.2) | 84 (7.8) | 0.665 | – |
| Sex (N) | 52 F/48 M | 40 F/60 M | 0.119 | – | 41 F/59 M | 47 F/53 M | 0.476 | – |
| Length of stay (median (IQR)) | 5 (5) | 6 (6) | 0.241 | – | 5 (8) | 5 (8) | 0.656 | – |
| DNR order on admission (%) | 38% | 39% | 0.999 | – | 37% | 33% | 0.656 | – |
| Survival to discharge (%) | 97% | 84% | 0.002 | 0.22 | 86% | 90% | 0.514 | – |
| Overall PC/GoC instances‡ (%) | 18% | 34% | 0.016 | 0.18 | 53% | 45% | 0.322 | – |
| PC/GoC by Dx (%) (n/N)§ | ||||||||
| Cancer | 53% (9/17) | 54% (15/28) | 0.999 | – | 53% (8/15) | 100% (18/18) | 0.002¶ | 0.57 |
| Chronic organ failure | 13% (2/15) | 31% (8/26) | 0.274¶ | – | 40% (10/25) | 52% (13/25) | 0.570 | – |
| Frailty | 10% (7/68) | 25% (11/43) | 0.062 | – | 60% (35/58) | 28% (14/50) | 0.002 | 0.32 |
*Tests compared Phase 1 and Phase 2, within each site—Student’s t-test for age, Mann-Whitney-Wilcoxon test for length of stay and Pearson’s χ2 tests with Yates’ continuity correction for all other variables.
†Cohen’s d for t-tests, r for Mann-Whitney-Wilcoxon tests, Cramér’s V for χ2 tests.
‡PC/GoC instances includes all consultations with PC and/or documented GoC discussions which occurred with the patient.
§Number of PC/GoC instances by diagnosis (n) over the total number of patients with that diagnosis (N).
¶A χ2 test with Monte Carlo simulation was done due <5 samples per cell.
DNR, Do Not Resusitate; Dx, Diagnosis; GoC, goals of care; PC, palliative care; mHOMR, modified version of Hospitalised-patient One-year Mortality Risk.